Hematology

  • Research Faculty

  • Show All

    Division Head

    A photo of Russell Ware.

    Russell E. Ware, MD, PhD Director, Division of Hematology

    is a recognized expert in sickle cell disease. He is the national PI for several NHLBI-funded sickle cell clinical trials, and has recently begun an international program to improve the diagnosis, treatment, and research for sickle cell disease in developing countries. His laboratory focuses on genetic modifiers of sickle cell disease, as well as the pharmacokinetics, pharmacodynamics, and pharmacogenetics of hydroxyurea therapy.
    Visit the Ware Lab.

    513-636-4266
    russell.ware@cchmc.org

    Russell E. Ware, MD, PhD

    Director, Division of Hematology

    Marjory J. Johnson Chair of Hematology Translational Research, Division of Hematology

    Co-Executive Director, Cancer and Blood Diseases Institute

    Associate Director, Global Health Center

    Academic Information

    Professor, UC Department of Pediatrics

    Phone: 513-636-4266

    Email: russell.ware@cchmc.org

    Show All

    Specialties

    Sickle cell disease; hemolytic anemia; immune-mediated cytopenia; PNH
    Visit the Ware Lab.

    Biography

    Russell Ware, MD, PhD, has been involved with a wide variety of clinical and translational hematology research projects for over 25 years, but his primary interests have focused on sickle cell disease. Dr. Ware has substantial personal experience with directing patient-oriented research, and he currently runs an NIH-funded laboratory effort that investigates genetic modifiers of sickle cell disease. The main focus of his lab research is to understand the phenotypic variability that occurs with hydroxyurea treatment, through the study of hydroxyurea pharmacokinetics, pharmacodynamics, pharmacogenetics, and pharmacogenomics. Dr. Ware is also the national Principal Investigator for several NIH-funded multicenter sickle cell clinical trials, including the recently completed Stroke With Transfusions Changing to Hydroxyurea (SWiTCH), and the current TCD With Transfusions Changing to Hydroxyurea (TWiTCH) and Sparing Conversion to Abnormal TCD Elevations (SCATE) studies that include non-US clinical sites. Most recently, Dr. Ware has moved his research efforts into the international arena, starting SCD pilot screening programs in Angola, and now conducting clinical trials to determine the safety and efficacy of hydroxyurea in developing countries.

    Education and Training

    MD: Duke University School of Medicine, Durham, NC, 1979-83.

    Residency: Baylor College of Medicine, Houston, TX, 1983-86.

    Fellowship: Duke Medical Center, Durham, NC, 1986-89.

    PhD: Duke University School of Medicine, Durham, NC, 1987-91.

    Certification: Pediatric Hematology/Oncology.

    Publications

    Faculty

    A photo of Ralph A. Gruppo.

    Ralph A. Gruppo, MD Director, Comprehensive Hemophilia and Thrombosis Center

    research involves numerous clinical trials of promising therapies for hemophilia, von Willebrand Disease, and hemolytic uremic syndrome. His research also includes the study of thrombosis in children, including the use of site-directed thrombolytic therapy in the prevention of long-term complications of thrombosis.

    513-636-4269
    ralph.gruppo@cchmc.org

    Ralph A. Gruppo, MD

    Director, Comprehensive Hemophilia and Thrombosis Center

    Director, Research Coagulation Laboratory

    Director, Special Hemostasis & Thrombosis Laboratory

    Academic Information

    Professor, UC Department of Pediatrics

    Phone: 513-636-4269

    Fax: 513-636-5845

    Email: ralph.gruppo@cchmc.org

    Show All

    Specialties

    Coagulation; hemophilia; thrombosis

    Education and Training

    MD: Johns Hopkins Medical School, Baltimore, MD, 1967.

    Residency: Children's Hospital Medical Center, Cincinnati, Ohio; Johns Hopkins School of Medicine, Baltimore, MD, 1970.

    Fellowship: Children's Hospital Medical Center, Cincinnati, OH, 1974.

    Certification: Pediatrics, 1975; Pediatric Hematology/Oncology, 1976.

    Publications

    View PubMed Publications
    A photo of Theodosia A. Kalfa.

    Theodosia A. Kalfa, MD, PhD

    focuses on the study of intracellular signals in erythropoiesis and mature red blood cells, specifically the signals conducted by Rho GTPases regulating terminal erythroid maturation and enucleation. Her lab also studies the role of Rac GTPases in generation of reactive oxygen species (ROS) within red blood cells from patients and animal models with sickle-cell disease along with the signaling mechanisms and consequences of increased ROS in sickle cells.
    Visit the Kalfa Lab.

    513-636-0989
    theodosia.kalfa@cchmc.org

    Theodosia A. Kalfa, MD, PhD

    Academic Information

    Associate Professor, UC Department of Pediatrics

    Phone: 513-636-0989

    Fax: 513-636-3549

    Email: theodosia.kalfa@cchmc.org

    Show All

    Specialties

    Signaling in erythrocytes; erythropoiesis; sickle cell disease; reactive oxygen species

    Visit the Kalfa Lab.

    Education and Training

    MD: Aristotle University Medical School, Thessaloniki, Greece, 1990.

    PhD: Aristotle University Medical School, Thessaloniki, Greece, 1997.

    Residency: University Of North Carolina, Chapel Hill, NC, 1999.

    Fellowship: Duke University Medical Center, Durham, NC, 2003.

    Certification: Hematology / oncology, American Board of Pediatrics, 2004; Pediatrics, American Board of Pediatrics, 2000; ECFMG Certification, 1995.

    Licenses: Full and unrestricted medical license (OH Medical Board), 2003-present; full and unrestricted license of medical practice in Greece, 1990-present.

    Publications

    View PubMed Publications

    Grants

    Rho GTPases in Terminal Erythroid Maturation. Principal Investigator. NIH/NHLBI. Sep 2012-Jun 2016. #1R01HL116352.

    Erythrocyte Cytoskeleton Disorders Diagnostic Core. Principal Investigator. CCTST PCS T1 Pilot. July 2013- June 2015.

    Cincinnati Center of Excellence in Hemoglobinopathies Research. Co-investigator. NIH/NHLBI. Aug 2013–May 2018. # U01 HL117709.

    TCD with Transfusions Changing to Hydroxyurea. Co-investigator. NIH/Baylor. Aug 2009-Jul 2014. #R01HL095647.

    A photo of Karen Kalinyak.

    Karen A. Kalinyak, MD Medical Director, Sickle Cell Clinic

    conducts research to understand the clinical course of sickle-cell disease and determine how to prevent or minimize complications. She served as local PI in numerous multi-institutional clinical trials, including Prophylactic Penicillin Study (PROPS II), Stroke with Transfusions Changing to Hydroxyurea (SWiTCH) Trial, Silent Infarct Transfusion Trial (SIT) and two SCD Clinical Research Network studies (PROACTIVE and IMPROVE).

    513-636-4266
    karen.kalinyak@cchmc.org

    Karen A. Kalinyak, MD

    Medical Director, Sickle Cell Clinic

    Academic Information

    Professor, UC Department of Pediatrics

    Phone: 513-636-4266

    Fax: 513-636-5845

    Email: karen.kalinyak@cchmc.org

    Show All

    Specialties

    Hematology; bone marrow failure; sickle cell anemia; hemoglobinopathy

    Education and Training

    MD: Temple University, Philadelphia, PA, 1977. 

    Residency: Children's Hospital Medical Center, Cincinnati, OH, 1980.

    Fellowship: Children's Hospital Medical Center, Cincinnati, OH, 1983.

    Certification: Pediatrics, 1984; Pediatric Hematology/Oncology, 1987.

    Publications

    View PubMed Publications
    A photo of Patrick McGann.

    Patrick T. McGann, MD, MS

    focuses his research efforts on improving the diagnosis, care, and outcomes for children with sickle cell anemia across the world, particularly in sub-Saharan Africa. Current projects include the investigation of hydroxyurea in Africa (REACH), the development and testing of inexpensive point-of-care diagnostics in hematology, and  analysis of serotype distribution of invasive pneumococcal disease in  Angola.

    513-803-4991
    patrick.mcgann@cchmc.org

    Patrick T. McGann, MD, MS

    Academic Information

    Assistant Professor, UC Department of Pediatrics

    Phone: 513-803-4991

    Email: patrick.mcgann@cchmc.org

    Show All

    Biography

    Dr. McGann was a leader in the development of a newborn screening and treatment program in the Republic of Angola. Toward this end, he worked and lived in Angola for much of two and a half years. This work helped to develop many relationships and is the foundation for much of his continued research and public health efforts in Angola. His research efforts during this time were supplemented by formal training in clinical research through the American Society of Hematology's Clinical Research Training Institute and through the master's program in clinical research at Baylor College of Medicine.

    He is also actively involved in global hematology and global child health through such organizations as the Global Sickle Cell Disease Network, the Central African Sickle Cell Network (REDAC), the American Society of Hematology, and the AAP's Section on International Child Health (SOICH). 

    Upon arrival to Cincinnati Children's, Dr. McGann was the recipient of the Procter Scholar Award, which will help to support his international research efforts.

    Education and Training

    MD: Tufts University School of Medicine, Boston, MA 2006.

    Residency: Pediatrics, Massachusetts General Hospital, Boston, MA 2009.

    Fellowship: Pediatric Hematology-Oncology, St. Jude Children's Research Hospital, 2009-2011; Baylor College of Medicine, 2011-2012.

    MS: Clinical Research, Baylor College of Medicine, 2013.

    Board Certification: Pediatrics, 2009; Pediatric Hematology-Oncology, 2013.

    Publications

    View PubMed Publications

    Grants

    Identification of serotype distribution causing invasive pneumococcal disease among Angolan children. Principal Investigator. Thrasher Research Fund-Early Career Award.  Aug 2012-July 2014.

    A Phase I/II Study of Hydroxyurea for Children with Sickle Cell Anemia in Angola. Principal Investigator. Procter Scholar Award, Cincinnanti Children's Hospital Medical Center TAPS Program. Jan 2014-Dec 2016.

    Sickle Cell Education and Screening for Angolan Adolescents. Co-Director/Mentor. AAP International Community Access to Child Health (ICATCH), Jan 2014-Dec 2016.

    A photo of Eric Mullins.

    Eric Mullins, MD

    has a research interest in the interplay between the hemostatic system and the immune system in the setting of inflammatory diseases and infection. 

    513-636-4266
    eric.mullins@cchmc.org

    Eric Mullins, MD

    Academic Information

    Assistant Professor, UC Department of Pediatrics

    Phone: 513-636-4266

    Fax: 513-636-3549

    Email: eric.mullins@cchmc.org

    Show All

    Specialties

    The interplay between the hemostatic system and the immune system in the setting of inflammatory diseases and infection.

    Education and Training

    MD: University of Missouri, Columbia.

    Residency: Vanderbilt University Medical Center, Nashville, Tenn.

    Fellowship: Pediatric Hematology / Oncology, Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio, 2008.
    A photo of Joseph Palumbo.

    Joseph S. Palumbo, MD

    focuses on interactions between the hemostatic system and innate immunity effecting tumor progression and Langerhans' cell histiocytosis.

    513-636-4266
    joe.palumbo@cchmc.org

    Joseph S. Palumbo, MD

    Academic Information

    Associate Professor, UC Department of Pediatrics

    Phone: 513-636-4266

    Fax: 513-636-3549

    Email: joe.palumbo@cchmc.org

    Show All

    Specialties

    Interactions between the hemostatic system and innate immunity effecting tumor progression; Langerhans' cell histiocytosis

    Education and Training

    MD: Pennsylvania State University College of Medicine, Hershey, PA, 1993. 

    Residency: Childrens Hospital Medical Center, Cincinnati, OH, 1997. 

    Fellowship: Childrens Hospital Medical Center, Cincinnati, OH, 2000.

    Subspecialty: Pediatric Hematology / Oncology.

    Publications

    View PubMed Publications

    Grants

    Mechanisms Linking Metastasis to Tumor Procoagulant and Innate Immunity. Principal Investigator. National Institutes of Health. Jul 2006 - Jun 2012. #R01HL085545.
    A photo of Charles Quinn, MD.

    Charles T. Quinn, MD, MS Director, Hematology Clinical and Translational Research

    investigates causes and ways to predict, prevent and treat brain injury in sickle cell disease, such as stroke and cognitive dysfunction, both locally in Cincinnati and as a member of national and international study teams. Other areas of research include developing a method to directly measure of red blood cell turnover rate in sickle cell disease, identification and treatment of cardiomyopathy and nephropathy in sickle cell disease, and new agents to treat and prevent pain (VOC) in sickle cell disease.

    513-636-4266
    charles.quinn@cchmc.org

    Charles T. Quinn, MD, MS

    Director, Hematology Clinical and Translational Research

    Director, Hemoglobinopathy Laboratory

    Academic Information

    Associate Professor, UC Department of Pediatrics

    Phone: 513-636-4266

    Fax: 513-636-5845

    Email: charles.quinn@cchmc.org

    Show All

    Specialties

    Clinical Interests

    Sickle cell disease; thalassemia; hemoglobinopathies; anemia; autoimmune hemolytic anemia; disorders of red blood cells; iron overload and iron chelation; chronic transfusion therapy; immune thrombocytopenia (ITP); neutropenia; stroke

    Research Interests

    Epidemiology, pathophysiology, treatment and prevention of brain injury (structural and cognitive) in sickle cell disease; measurement of red blood cell turnover in sickle cell disease; identification and treatment of cardiomyopathy and nephropathy in sickle cell disease; treatment and prevention of pain (VOC) in sickle cell disease; MRI methods of iron quantitation; new agents for immune thrombocytopenia (ITP)

    Biography

    Dr. Quinn’s main interests and expertise are in patient-oriented and translational research in sickle cell disease and thalassemia. His formal clinical and translational research training has included: (1) the NIH-K30 Curriculum in Patient-Oriented Research; (2) the Clinical Research Training Institute of the American Society of Hematology; (3) the NIH-K12/KL2 Clinical Scholars Program; and (4) a master’s degree in clinical sciences. Dr. Quinn is a member of the Editorial Board for Pediatric Blood and Cancer and the Board of Contributing Editors for The Hematologist. Dr. Quinn is on the Medical Advisory Board for the Cooley’s Anemia Foundation, and he is a member of the Committee on Educational Affairs of the American Society of Hematology. Locally, he is the medical director of the Ohio Department of Health Regional Sickle Cell Services Program – Region 1.

    Education and Training

    MD:  University of Texas Southwestern Medical Center, Dallas, TX, 1994.

    MS:  University of Texas Southwestern Medical Center, Dallas, TX, 2008.

    Residency & Chief Residency: Children's Medical Center Dallas, Dallas, TX; University of Texas Southwestern Medical Center, Dallas, TX, 1998.

    Fellowship:  Children's Medical Center Dallas, Dallas, TX; University of Texas Southwestern Medical Center, Dallas, TX, 2001.

    Certifications: Pediatrics, 1998; Pediatric Hematology-Oncology, 2002.

    Publications

    View PubMed Publications

    Grants

    A feasibility study of regadenoson for the treatment of acute chest syndrome. Co-investigator. National Institutes of Health. April 2012-March 2017. P50HL110790.

    Cincinnati Center of Excellence in Hemoglobinopathies Research. Co-PI. National Institutes of Health. Aug 2013–May 2018. U01 HL117709.

    A Phase 3, Double-Blind, Randomized, Efficacy and Safety Comparison of Prasugrel and Placebo in Pediatric Patients with Sickle Cell Disease. Co-Investigator. Eli Lilly and Co. Jan 2013–Dec 2015.

    Evaluation of Purified Poloxamer 188 in Children in Crisis (EPIC): A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Trail of ANX-188 (Purified Poloxamer 188) Injection in Children with Sickle Cell Disease Experiencing Vaso-Occlusive Crisis. Co-Investigator. MAST Therapeutics. Nov 2012–Dec 2015.

    Safety and Efficacy Study of Romiplostim to Treat ITP in Pediatric Subjects. Co-Investigator. Amgen Inc. Oct 2013–Dec 2015.

    A photo of Susan Rose.

    Susan R. Rose, MD

    investigates hypothalamic pituitary function and disorders of growth, puberty or thyroid hormone. She has special interest in the effects of neural injury on hypothalamic-pituitary function, such as after traumatic brain injury, cranial radiation, anoxia, iron overload.

    513-636-4744
    susan.rose@cchmc.org

    Susan R. Rose, MD

    Academic Information

    Professor, UC Department of Pediatrics

    Phone: 513-636-4744

    Email: susan.rose@cchmc.org

    Show All

    Specialties

    Clinical

    Neuro-endocrinology; hypothalamic-pituitary injury; growth disorders; puberty disorders; thyroid disorders; late effects of cancer

    Research

    Hypothalamic-pituitary function

    Biography

    Susan Rose is professor in the Division of Endocrinology at Cincinnati Children’s Hospital Medical Center and the University of Cincinnati. She has published over 100 review articles or chapters, and about 100 peer-reviewed articles. These include updating guidelines for care of congenital hypothyroidism and writing the chapter on thyroid for Fanaroff's and Avery's textbooks of neonatology. She’s served on the state newborn screening (NBS) committee in Tennessee. She is involved in long term follow up of newborn screening for CAH and congenital hypothyroidism with Region 4 and with the Federal Workgroup on NBS Standards.

    She has clinical expertise and research interests in hypothalamic pituitary function, thyroid hormone disorders, and in disorders of growth or puberty. She has a special interest in the effects of central nervous system injury on hypothalamic-pituitary function. In addition, she has expertise and experience in evaluating the endocrine conditions associated with congenital bone marrow failure syndromes such as Fanconi anemia, Blackfan Diamond anemia, and Shwachman-Diamond syndrome. In addition, she is evaluating the endocrine consequences of hypothalamic-pituitary injury, including traumatic brain injury and injury from treatments for cancer, as well as comparing the relative efficacy of several treatments for precocious puberty. In this study, she will be developing growth curves specific to Fanconi Anemia, recognizing that healthy children with FA may not grow along the typical growth pattern of other healthy children.

    Education and Training

    MD: Case Western Reserve School of Medicine, 1980.

    MEd: School Psychology, University of Dayton, 1972.

    Residency: The Cleveland Clinic, 1983.

    Fellowship: National Institutes of Health, 1986.

    Certification: Pediatrics, 1985; Pediatric Endocrinology, 1986.

    Publications

    View PubMed Publications
    A photo of Cristina Tarango.

    Cristina Tarango, MD Medical Director, Hemophilia Treatment Center

    research focuses on pediatric thrombosis and hemostasis. She also has an interest in medical education.

    513-636-4266
    cristina.tarango@cchmc.org

    Cristina Tarango, MD

    Medical Director, Hemophilia Treatment Center

    Clinical Director, Division of Hematology

    Academic Information

    Assistant Professor, UC Department of Pediatrics

    Phone: 513-636-4266

    Fax: 513-636-6927

    Email: cristina.tarango@cchmc.org

    Show All

    Specialties

    Pediatric bleeding disorders and thrombosis; quality improvement; medical education

    Education and Training

    MD: Stanford University School of Medicine, Stanford, CA, 2003.

    Residency: Yale-New Haven Hospital, New Haven, CT, 2006.

    Fellowship: University of Texas Southwestern Medical Center Dallas, Dallas, TX, 2009.

    Certification: Pediatrics, 2006. Pediatric Hematology Oncology, 2011.

    Publications